ArticleJournal of immunological methods2012
Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8.
Article in Journal of immunological methods, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Activated sputum eosinophils associated with exacerbations in children on mepolizumab.The Journal of allergy and clinical immunology · 2024Trial
- Siglec-8 as a Biomarker for Predicting Anti-IL-5 Response in Severe Asthma.Allergy, asthma & immunology research · 2025Article
- Eosinophils as potential biomarkers in respiratory viral infections.Frontiers in immunology · 2023Review
- Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma.Cancers · 2022Article
- Intestinal proline is a potential anti-allergy factor for allergy diagnosis and therapy.Frontiers in nutrition · 2022Article
- First Evidence for a Role of Siglec-8 in Breast Cancer.International journal of molecular sciences · 2021Article
- Siglec Signaling in the Tumor Microenvironment.Frontiers in immunology · 2021Review
- Eosinophil and mast cell Siglecs: From biology to drug target.Journal of leukocyte biology · 2020Review
- Phosphodiesterase 4 inhibitors attenuate virus-induced activation of eosinophils from asthmatics without affecting virus binding.Pharmacology research & perspectives · 2020Article
- Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies.The Journal of allergy and clinical immunology · 2019Article
- Epigenome-wide association study reveals methylation pathways associated with childhood allergic sensitization.Epigenetics · 2019Article
- Reuse of public, genome-wide, murine eosinophil expression data for hypotheses development.Journal of leukocyte biology · 2018Article
- Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.The Journal of allergy and clinical immunology · 2018Article
- Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.Current opinion in allergy and clinical immunology · 2016Review
- Eosinophilic bioactivities in severe asthma.The World Allergy Organization journal · 2016Review
- Novel Therapies for Eosinophilic Disorders.Immunology and allergy clinics of North America · 2015Review
- Novel targeted therapies for eosinophil-associated diseases and allergy.Annual review of pharmacology and toxicology · 2015Review
- Activation states of blood eosinophils in asthma.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2014Review
- The role of lung epithelial ligands for Siglec-8 and Siglec-F in eosinophilic inflammation.Current opinion in allergy and clinical immunology · 2013Review
- Biologic therapies targeting eosinophils: current status and future prospects.The journal of allergy and clinical immunology. In practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
There remains considerable controversy in the management of eosinophilic disorders, mainly due to a paucity of information regarding the clinical interpretation of total blood eosinophil counts versus surface activation markers versus eosinophil-derived or eosinophil-influencing mediator levels. Regrettably, few tests have been validated that define a unique clinical or prognostic phenotype that is more useful than simply monitoring total blood eosinophil counts. In this manuscript, phenotypic (cell surface) markers, along with serum and tissue-based markers that have been examined in the context of disease activity, are reviewed. We also report the development of a novel assay for detecting soluble Siglec-8 (sSiglec-8), a protein likely derived largely from eosinophils, as a potential serum biomarker. The assay consists of a competitive ELISA using a recombinant Siglec-8-Fc fusion protein. The goal of this preliminary study was to determine if sSiglec-8 is a useful biomarker that differentiates among patients with various eosinophil-associated diseases. In the final analysis, it is fair to say that further research is sorely needed to fully understand and validate the utility of various biomarkers, including sSiglec-8, before their use in clinical practice can be recommended with confidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.